Announcement PDF MARKET RELEASE 3 December 2015 Neuren Pharmaceuticals Limited TRADING HALT The securities of Neuren Pharmaceuticals Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 7 December 2015 or when the announcement is released to the market. Security Code: NEU Violetta Codreanu ADVISER, LISTINGS COMPLIANCE (SYDNEY) ASX Compliance Pty Limited ABN 26 087 780 489 20 Bridge Street Sydney NSW 2000 www.asx.com.au Customer service 13 12 79 3 December 2015 Violetta Codreanu ASX Compliance Pty Limited 20 Bridge Street Sydney NSW 2000 By Email Dear Violetta, TRADING HALT REQUEST The Directors of Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby request a halt in trading of the Company’s securities, effective until market opening on Monday 7 December 2015, or an earlier announcement by the Company. The trading halt is requested pending an announcement regarding Neuren’s Phase 2 clinical trial of trofinetide in Fragile X syndrome. The Company is not aware of any reason why the trading halt should not be granted. Yours sincerely Jon Pilcher CFO & Company Secretary Neuren Pharmaceuticals Limited ARBN 111 496 130 Suite 201, 697 Burke Road, Camberwell, VIC 3124